Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

Federal University of São Paulo71 enrolled

Overview

Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment. Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER and progesterone- PR), some patients become hormone resistant. In order to identify a possible profile associated to hormonal resistance, some biomarkers have been assessed after short period primary hormone therapy (HT). Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and anastrozole in short term hormone therapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Breast Cancer

Interventions

Eligibility

Sex: FEMALEMin age: 40 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Invasive breast cancer post-menopausal women * Estrogen and/or progesterone receptor positive Exclusion Criteria: * Patients with endocrine disease * Hormone therapy users or those who had been pregnant in the last 12 months before the diagnosis * Patients with a negative expression for estrogen and/or progesterone receptors * Women with a history of thromboembolism * Patients who had previously undergone any treatment for breast cancer

Outcomes

Primary Outcomes

Expression of progesterone

Time frame: end of the study (june 2008)

Secondary Outcomes

Expression of Ki-67